Biosimilar insulins: Basic considerations

Journal of Diabetes Science and Technology

Volumn 8, Issue 1, 2014, Pages 6-13

  Heinemann, Lutz ^a   Hompesch, Marcus ^b  

^a Science and Co   (Germany)

^b Profil Institute for Clinical Research   (United States)

Author keywords

Biosimilar insulin; Insulin analogs; Insulin antibodies; Insulin formulations; Insulin glargine; Insulin therapy

Indexed keywords

BIOSIMILAR AGENT; BIOSIMILAR INSULIN; GLUCOSE; INSULIN ANTIBODY; INSULIN DERIVATIVE; UNCLASSIFIED DRUG;

CONFERENCE PAPER; DRUG APPROVAL; DRUG COST; DRUG DEVELOPMENT; DRUG FORMULATION; DRUG INDUSTRY; DRUG LEGISLATION; DRUG MANUFACTURE; DRUG MARKETING; DRUG SCREENING; FOOD AND DRUG ADMINISTRATION; GLUCOSE CLAMP TECHNIQUE; HUMAN; INSULIN TREATMENT; MEDICAL TECHNOLOGY; NONHUMAN; QUALITY CONTROL; THERAPEUTIC EQUIVALENCE;

EID: 84900558411     PISSN: None     EISSN: 19322968     Source Type: Journal    
DOI: 10.1177/1932296813516958     Document Type: Conference Paper

References (13)

1. Sekhon BS, Saluja V. Biosimilars: an overview. Biosimilars. 2011;1:1-11.
2. Roger SD. Biosimilars: current status and future directions. Expert Opin Biol Ther. 2010;10:1011-1018.
3. Kresse GB. Biosimilars - science, status, and strategic perspective. Eur J Pharm Biopharm. 2009;72:479-486.
4. Weise M, Bielsky MC, De SK, et al. Biosimilars-why terminology matters. Nat Biotechnol. 2011;29:690-693.
5. Kuhlmann M, Covic A. The protein science of biosimilars. Nephrol Dial Transplant. 2006;21(suppl 5):v4-v8.
6. Kannan V, Narayanaswamy P, Gadamsetty D, Hazra P, Khedkar A, Iyer H. A tandem mass spectrometric approach to the identification of O-glycosylated glargine glycoforms in active pharmaceutical ingredient expressed in Pichia pastoris. Rapid Commun Mass Spectrom. 2009;23:1035-1042.
7. Owens DR, Landgraf W, Schmidt A, Bretzel RG, Kuhlmann MK. The emergence of biosimilar insulin preparations - a cause for concern? Diabetes Technol Ther. 2012;14:989-996.
8. Heinemann L, Hompesch M. Biosimilar insulins: how similar is similar? J Diabetes Sci Technol. 2011;5:741-754.
9. Swinnen SG, Holleman F, DeVries JH. The interpretation of glucose clamp studies of long-acting insulin analogues: from physiology to marketing and back. Diabetologia. 2008;51:1790-1795.
10. Cheng SW, Lu J, Pan C, et al. Studies of pharmacokinetic, pharmacodynamic properties and bioequivalence of recombinant insulin glargine injection in healthy man. Chin J Diabetes. 2010;18:387-393.
11. Zib I, Raskin P. Novel insulin analogues and its mitogenic potential. Diabetes Obes Metab. 2006;8:611-620.
12. Praditpornsilpa K, Tiranathanagul K, Kupatawintu P, et al. Biosimilar recombinant human erythropoietin induces the production of neutralizing antibodies. Kidney Int. 2011;80:88-92.
13. Hazell L, Shakir SA. Under-reporting of adverse drug reactions: a systematic review. Drug Saf. 2006;29:385-396.